Illustration: The intersection of GLP-1 pharmacology and female cancer biology · Happysimus · Physician-reviewed

There are moments in medicine when a finding arrives and the room goes quiet. Not because it is definitive — often it isn’t — but because the implications, if confirmed, could be genuinely transformative. The study presented at the 2026 American Society of Clinical Oncology Annual Meeting and simultaneously published in JCO Oncology Practice is one of those moments.

Ozempic, Wegovy, Mounjaro, Zepbound — the GLP-1 drugs that have dominated conversation for their weight loss effects — may also be associated with a significantly reduced risk of breast cancer. As a physician who works with women every day, I want to take you carefully through what this study actually shows, what questions it leaves open, and what it means — practically — for the women reading this right now.

The Study That Changed the Conversation

Researchers at the University of Pennsylvania Perelman School of Medicine analysed electronic health records from 111,646 women aged 45 to 80 with a BMI of 25 or above, all of whom had undergone breast imaging between January 2022 and June 2025. Of those women, 13.7% had documented GLP-1 prescriptions — Ozempic, Wegovy, Mounjaro, Zepbound — and 86.3% had not.

According to ScienceDaily, the results were striking. Women on GLP-1 medications had 35.1% lower odds of developing breast cancer in the full cohort analysis. In the more rigorous matched analysis — where researchers controlled for age, race, ethnicity, BMI, breast density, and diabetes status — the odds were still 30.5% lower. That matched analysis matters because it reduces the possibility that the effect is simply due to GLP-1 users being healthier in other ways to begin with.

“While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools,” said lead researcher Dr. Elizabeth McDonald, Professor of Radiology at Penn. A clinical trial has now been launched to investigate the causal relationship.

Why Would Ozempic Affect Breast Cancer Risk?

This is the question the oncology community is most energised about — and it has a surprisingly elegant answer rooted in endocrinology. Understanding it requires a short detour into how obesity and breast cancer are connected. Penn Medicine explains it clearly: after menopause, the ovaries stop producing oestrogen. But fat cells do not. They continue producing it via a process involving the enzyme aromatase — and the more fat tissue a woman carries, the more oestrogen her body produces.

The biological pathway linking excess adipose tissue to elevated breast cancer risk — and where GLP-1 drugs intervene

High circulating oestrogen is a well-established driver of oestrogen receptor-positive (ER+) breast cancer — the most common type. GLP-1 drugs reduce adipose tissue, which reduces oestrogen production, which reduces one of the primary hormonal drivers of tumour growth. That is the straightforward part of the story.

But there is also a second mechanism — and Medical News Today’s detailed analysis covers it well. Excess fat tissue operates as what researchers call an “inflammatory endocrine organ,” secreting cytokines including TNF-α, IL-6, and leptin that promote chronic low-grade inflammation. This inflammation both encourages tumour-promoting signalling pathways and suppresses the immune system’s capacity to fight nascent cancer cells. GLP-1 drugs reduce this inflammatory burden independently of weight loss — a finding with potentially profound implications.

Beyond Weight Loss — Is There a Direct Anti-Cancer Effect?

This is where the science becomes particularly compelling — and where I urge appropriate caution in equal measure. Scientific American reports that in animal studies, tirzepatide — the dual-receptor drug sold as Zepbound and Mounjaro — appears to have direct effects on breast cancer and endometrial cancer tumours, possibly by reversing inflammatory effects and inhibiting tumour growth through GLP-1 receptors present on breast tissue itself.

Research from the Cleveland Clinic adds another dimension: across seven tumour types, patients whose tumours were packed with GLP-1 receptors were 33% less likely to die during the follow-up period — with breast cancer patients showing the greatest improvements in survival. These are early findings, but they point toward a direct pharmacological effect that goes well beyond metabolic improvement.

Who Should Pay Attention to This

The study population was women aged 45–80 with a BMI of 25 or above. That is not a narrow demographic. Roughly two thirds of adult women in the United States meet the BMI criterion. Add the age range and you are talking about tens of millions of women for whom this research has potential relevance.

Particularly relevant groups include: postmenopausal women with overweight or obesity (where the oestrogen-via-fat-tissue mechanism is most active); women with a family history of breast cancer who are seeking risk reduction strategies; women who are already prescribed GLP-1 medications for diabetes or weight management and were unaware of this potential secondary benefit; and women in perimenopause, a period during which weight management has outsized hormonal consequences. As the Breast Cancer Research Foundation notes, “maintaining a healthy weight in perimenopause and menopause is so important” — and GLP-1 drugs appear to support this in ways that go beyond what diet and exercise alone typically achieve.

What the Study Cannot Tell Us Yet

Intellectual honesty requires being clear about the limits of this research, and I would be failing you as a clinician if I glossed over them. This is an observational, retrospective study. It found an association — not a proven causal relationship. There are several important gaps:

• →No drug-specific breakdown: Ozempic, Wegovy, Mounjaro and Zepbound were all grouped together. We do not yet know whether the effect differs between semaglutide and tirzepatide.
• →No data on duration: How long do women need to be on these drugs before a protective effect emerges? The study did not measure this.
• →Genetic risk not accounted for: BRCA1 and BRCA2 carriers have a very different risk profile. This was not captured.
• →Cancer type and stage not specified: Whether the protective effect applies equally to all breast cancer subtypes remains unknown.
• →Correlation vs. causation: Women prescribed GLP-1 drugs may differ from non-users in other health behaviours. Despite the matched analysis, residual confounding cannot be ruled out.

The clinical trial that has been launched in response to these findings will begin to answer these questions. Until those results are available, this evidence should be understood as hypothesis-generating and promising — not practice-changing for individual women without other clinical indications for GLP-1 therapy.

An OB-GYN’s Honest Perspective

I want to speak to you plainly, the way I would if you were sitting across from me in a consultation room. This study is exciting. The sample size is large, the methodology is credible, the biological plausibility is strong, and the implications — if confirmed — are significant for millions of women. It is exactly the kind of finding that makes evidence-based medicine worth following.

But I would not recommend that any woman start a GLP-1 medication specifically because of this study. Here is why: these medications carry their own profile of side effects — nausea, gastrointestinal disturbance, and rarer but serious risks including pancreatitis and thyroid changes — and they are currently indicated for specific conditions. Using them as a cancer prevention tool, without established indication, goes beyond what the current evidence supports.

What I would say is this: if you are already on a GLP-1 medication for diabetes or weight management, this study adds to the reasons to take that prescription seriously. If you are a postmenopausal woman with overweight or obesity who has been considering GLP-1 therapy, this research is a legitimate and meaningful part of the conversation to have with your doctor — not the only consideration, but a real one. And if you carry elevated breast cancer risk, ask your oncologist or gynaecologist whether this study changes anything about your monitoring or prevention strategy.

The Bottom Line

A drug that was already transforming conversations about weight, diabetes, and cardiovascular health has now entered the oncology conversation with considerable force. The Penn Medicine study does not prove that Ozempic prevents breast cancer. But it raises that possibility with a strength of signal — 30 to 35% risk reduction, in 111,000 women, persistent after controlling for known confounders — that the medical community cannot responsibly ignore.

The clinical trial will tell us more. Until then, the appropriate response is neither dismissal nor rush — it is informed, thoughtful conversation between women and the clinicians who care for them. That conversation just got significantly more interesting.